SK Biopharm, Supply Agreement for Senobamate Sales in the United States
[Asia Economy Reporter Hwang Junho] SK Biopharm announced on the 22nd that it has signed a product supply contract worth 14.3155 billion KRW with SK Life Science, Inc., SK Biopharm's local subsidiary in the United States, for the sale of the new epilepsy treatment drug Cenobamate (product name: XCOPRI®) in the U.S. market. The contract period will run from today until February 28 of next year.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
